ACXP ACURX PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ACURX PHARMACEUTICALS INC reported revenue of n/a, net income of −$2.25M and diluted EPS of −$0.53; for the fiscal year ended December 2025 revenue was n/a.
ACXP annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$8.09M, net income −$7.97M (margin n/a), EPS −$5.32
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$14.1M, net income −$14.1M (margin n/a), EPS −$17.45
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$14.6M (margin n/a), EPS −$1.15
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$12.1M (margin n/a), EPS −$1.12
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$12.7M (margin n/a), EPS −$1.49
ACXP quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.25M, EPS −$0.53
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.68M, EPS −$0.62
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$1.58M, EPS −$0.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.99M, EPS −$1.23
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.25M, EPS −$1.89
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.15M, EPS −$2.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.78M, EPS −$8.51
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.82M, EPS −$3.45
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.12M, EPS −$5.21
- Quarter ended Mar 31, 2024: revenue n/a, net income −$4.38M, EPS −$0.28
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.11M, EPS −$0.38
- Quarter ended Sep 30, 2023: revenue n/a, net income −$3.11M, EPS −$0.24
- Quarter ended Jun 30, 2023: revenue n/a, net income −$3.45M, EPS −$0.28
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.90M, EPS −$0.25
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.26M, EPS −$0.28
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.54M, EPS −$0.32
- Quarter ended Jun 30, 2022: revenue n/a, net income −$2.62M, EPS −$0.26
- Quarter ended Mar 31, 2022: revenue n/a, net income −$2.67M, EPS −$0.26
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.63M, EPS −$0.25
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.64M, EPS −$0.46
ACXP cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.79M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$10.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$9.80M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$7.54M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$5.01M, share buybacks n/a
ACXP balance sheet
- Jun 30, 2026: cash n/a, total assets $11.0M, total liabilities $2.83M, shareholders' equity $8.15M
- Mar 31, 2026: cash n/a, total assets $9.54M, total liabilities $2.53M, shareholders' equity $7.01M
- Dec 31, 2025: cash n/a, total assets $7.69M, total liabilities $2.42M, shareholders' equity $5.27M
- Sep 30, 2025: cash n/a, total assets $6.11M, total liabilities $2.47M, shareholders' equity $3.64M
- Dec 31, 2024: cash n/a, total assets $3.86M, total liabilities $3.24M, shareholders' equity $615K
- Jun 30, 2024: cash n/a, total assets $6.58M, total liabilities $3.15M, shareholders' equity $3.43M
- Mar 31, 2024: cash n/a, total assets $9.11M, total liabilities $3.11M, shareholders' equity $6.00M
- Dec 31, 2023: cash n/a, total assets $7.71M, total liabilities $3.04M, shareholders' equity $4.67M
Is ACXP profitable?
No. ACURX PHARMACEUTICALS INC lost $7.51M over the last four quarters.
What is ACXP's EPS?
Diluted earnings per share over the last four quarters were −$2.43; −$0.53 in the latest quarter.